Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | RAD52 | P43351 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3596455 | 1.00 | ALOX15 (0.39) | ALOX15SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL25328099 | 0.83 | ALDH1A1 (0.42) | SMYD2CYP3A4HTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL18082177 | 0.82 | SMYD2 (0.38) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL5026278 | 0.82 | SMYD2 (0.38) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL5026273 | 0.82 | SMYD2 (0.38) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL31645264 | 0.81 | SMYD2 (0.37) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL18082187 | 0.80 | SMYD2 (0.37) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL8174758 | 0.80 | ALDH1A1 (0.36) | SMYD2CYP3A4HTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL8174756 | 0.80 | ALDH1A1 (0.36) | SMYD2CYP3A4HTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL31645258 | 0.79 | SMYD2 (0.38) | SMYD2CYP3A4HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093842-A1 | Laulimalide Analogs and Uses Thereof | EISAI CO. LTD. | 2010-04-15 | — | — | US | disclosed |
| US-20070287745-A1 | Laulimalide Analogs and Uses Thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093842-A1 | Laulimalide Analogs and Uses Thereof | LPXN, MLX, ZYX | ALOX15 741/4885SMYD2 919/4885CYP3A4 4193/4885 |
| US-20070287745-A1 | Laulimalide Analogs and Uses Thereof | LPXN, MLX, ZYX | ALOX15 741/4885SMYD2 919/4885CYP3A4 4193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.